Figure 1 | Scientific Reports

Figure 1

From: Serum C-reactive protein and albumin are useful biomarkers for tight control management of Crohn’s disease in Japan

Figure 1

The cumulative incidence rates of major adverse outcomes. When comparing groups divided according to serum CRP or Alb levels at week 8 or 24, the cumulative incidence rate was significantly higher in the patients with CRP ≥ 0.5 mg/dL at week 8 (a), Alb < 3.8 g/dL at week 8 (b), CRP ≥ 0.5 mg/dL at week 24 (c), and Alb < 3.8 g/dL at week 24 (d). Alb: albumin; CRP: C-reactive protein; MAOs: major adverse outcomes (hospitalization related to worsening of Crohn’s disease, surgery, and discontinuation of anti-tumor necrosis factor agents due to treatment failure).

Back to article page